227 related articles for article (PubMed ID: 19490823)
1. Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis.
Leahy JL
Curr Diab Rep; 2009 Jun; 9(3):215-20. PubMed ID: 19490823
[TBL] [Abstract][Full Text] [Related]
2. Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective.
Dumasia R; Eagle KA; Kline-Rogers E; May N; Cho L; Mukherjee D
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Oct; 5(5):377-86. PubMed ID: 16248830
[TBL] [Abstract][Full Text] [Related]
3. The role of peroxisome proliferator-activated receptor γ in pancreatic β cell function and survival: therapeutic implications for the treatment of type 2 diabetes mellitus.
Gupta D; Kono T; Evans-Molina C
Diabetes Obes Metab; 2010 Dec; 12(12):1036-47. PubMed ID: 20977574
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones and PPARγ agonists: time for a reassessment.
Cariou B; Charbonnel B; Staels B
Trends Endocrinol Metab; 2012 May; 23(5):205-15. PubMed ID: 22513163
[TBL] [Abstract][Full Text] [Related]
5. What are the pharmacotherapy options for treating prediabetes?
Daniele G; Abdul-Ghani M; DeFronzo RA
Expert Opin Pharmacother; 2014 Oct; 15(14):2003-18. PubMed ID: 25139488
[TBL] [Abstract][Full Text] [Related]
6. Impact of alogliptin and pioglitazone on lipid metabolism in islets of prediabetic and diabetic Zucker Diabetic Fatty rats.
Cai Y; Lydic TA; Turkette T; Reid GE; Olson LK
Biochem Pharmacol; 2015 May; 95(1):46-57. PubMed ID: 25801003
[TBL] [Abstract][Full Text] [Related]
7. Diabetes: New conductors for the peroxisome proliferator-activated receptor γ (PPARγ) orchestra.
Whitehead JP
Int J Biochem Cell Biol; 2011 Aug; 43(8):1071-4. PubMed ID: 21558015
[TBL] [Abstract][Full Text] [Related]
8. beta-cell failure in diabetes and preservation by clinical treatment.
Wajchenberg BL
Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
[TBL] [Abstract][Full Text] [Related]
9. [The role of peroxisome proliferator-activated receptor gamma in the pathogenesis of diabetes and atheromatosis].
Gacka M; Adamiec R; Dobosz T; Szymaniec S; Bednarska-Chabowska D
Przegl Lek; 2004; 61(12):1436-9. PubMed ID: 15850344
[TBL] [Abstract][Full Text] [Related]
10. Adiponectin increases insulin content and cell proliferation in MIN6 cells via PPARγ-dependent and PPARγ-independent mechanisms.
Rao JR; Keating DJ; Chen C; Parkington HC
Diabetes Obes Metab; 2012 Nov; 14(11):983-9. PubMed ID: 22594400
[TBL] [Abstract][Full Text] [Related]
11. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus.
Walter H; Lübben G
Drugs; 2005; 65(1):1-13. PubMed ID: 15610048
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones and type 2 diabetes: from cellular targets to cardiovascular benefit.
Papaetis GS; Orphanidou D; Panagiotou TN
Curr Drug Targets; 2011 Sep; 12(10):1498-512. PubMed ID: 21675944
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.
Armato J; DeFronzo RA; Abdul-Ghani M; Ruby R
Endocr Pract; 2012; 18(3):342-50. PubMed ID: 22068250
[TBL] [Abstract][Full Text] [Related]
14. Possible Protective Effects of Thiazolidinediones Antidiabetic Drugs in Colorectal Cancer.
Bahrambeigi S; Badalzadeh R; Shafiei-Irannejad V; Alizadeh A
Crit Rev Oncog; 2019; 24(3):251-258. PubMed ID: 32422023
[TBL] [Abstract][Full Text] [Related]
15. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
Fogo AB
Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
[TBL] [Abstract][Full Text] [Related]
16. The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective.
Ahsan W
Curr Pharm Des; 2019; 25(23):2540-2554. PubMed ID: 31333088
[TBL] [Abstract][Full Text] [Related]
17. A selective peroxisome proliferator-activated receptor-gamma modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones.
Tagami T; Yamamoto H; Moriyama K; Sawai K; Usui T; Shimatsu A; Naruse M
Endocrinology; 2009 Feb; 150(2):862-70. PubMed ID: 19147680
[TBL] [Abstract][Full Text] [Related]
18. Recent findings concerning thiazolidinediones in the treatment of diabetes.
Boden G; Zhang M
Expert Opin Investig Drugs; 2006 Mar; 15(3):243-50. PubMed ID: 16503761
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
Quinn CE; Hamilton PK; Lockhart CJ; McVeigh GE
Br J Pharmacol; 2008 Feb; 153(4):636-45. PubMed ID: 17906687
[TBL] [Abstract][Full Text] [Related]
20. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
